|
1
|
Sala A, Mattano LA Jr and Barr RD:
Osteonecrosis in children and adolescents with cancer-an adverse
effect of systemic therapy. Eur J Cancer. 43:683–689. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kadan-Lottick NS, Dinu I,
Wasilewski-Masker K, Kaste S, Meacham LR, Mahajan A, Stovall M,
Yasui Y, Robison LL and Sklar CA: Osteonecrosis in adult survivors
of childhood cancer: A report from the childhood cancer survivor
study. J Clin Oncol. 26:3038–3045. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Davies JH, Evans BA, Jenney ME and Gregory
JW: Skeletal morbidity in childhood acute lymphoblastic leukaemia.
Clin Endocrinol (Oxf). 63:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Faraci M, Calevo MG, Lanino E, Caruso S,
Messina C, Favr C, Iori A, Santaron S, Bonanomi S, Rondelli R, et
al: Osteonecrosis after allogeneic stem cell transplantation in
childhood. A case-control study in Italy. Haematologica.
91:1096–1099. 2006.PubMed/NCBI
|
|
5
|
Davies JH, Evans BA, Jenney ME and Gregory
JW: In vitro effects of chemotherapeutic agents on human
osteoblast-like cells. Calcif Tissue Int. 70:408–415. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tillmann V, Darlington AS, Eiser C, Bishop
NJ and Davies HA: Male sex and low physical activity are associated
with reduced spine bone mineral density in survivors of childhood
acute lymphoblastic leukemia. J Bone Miner Res. 17:1073–1080. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Warner JT, Evans WD, Webb DK, Bell W and
Gregory JW: Relative osteopenia after treatment for acute
lymphoblastic leukemia. Pediatr Res. 45:544–551. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Relling MV, Yang W, Das S, Cook EH, Rosner
GL, Neel M, Howard S, Ribeiro R, Sandlund JT, Pui CH and Kaste SC:
Pharmacogenetic risk factors for osteonecrosis of the hip among
children with leukemia. J Clin Oncol. 22:3930–3936. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zalavras CG, Malizos KN, Dokou E and
Vartholomatos G: The 677C->T mutation of the
methylene-tetrahydrofolate reductase gene in the pathogenesis of
osteonecrosis of the femoral head. Haematologica. 87:111–112.
2002.PubMed/NCBI
|
|
10
|
French D, Hamilton LH, Mattano LA Jr,
Sather HN, Devidas M, Nachman JB and Relling MV: Children's
Oncology Group: A PAI-1 (SERPINE1) polymorphism predicts
osteonecrosis in children with acute lymphoblastic leukemia: A
report from the Children's Oncology Group. Blood. 111:4496–4499.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mei L, Ontiveros EP, Griffith EA, Thompson
JE, Wang ES and Wetzler M: Pharmacogenetics predictive of response
and toxicity in acute lymphoblastic leukemia therapy. Blood Rev.
29:243–249. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hunger SP and Mullighan CG: Acute
lymphoblastic leukemia in children. N Engl J Med. 373:1541–1552.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Glueck CJ, Freiberg RA, Fontaine RN, Tracy
T and Wang P: Hypofibrinolysis, thrombophilia, osteonecrosis. Clin
Orthop Relat Res. 19–33. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ralston SH and de Crombrugghe B: Genetic
regulation of bone mass and susceptibility to osteoporosis. Genes
Dev. 20:2492–2506. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ioannidis JP, Ralston SH, Bennett ST,
Brandi ML, Grinberg D, Karassa FB, Langdahl B, van Meurs JB,
Mosekilde L, Scollen S, et al: Differential genetic effects of ESR1
gene polymorphisms on osteoporosis outcomes. JAMA. 292:2105–2114.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ralston SH, Uitterlinden AG, Brandi ML,
Balcells S, Langdahl BL, Lips P, Lorenc R, Obermayer-Pietsch B,
Scollen S, Bustamante M, et al: Large-scale evidence for the effect
of the COLIA1 Sp1 polymorphism on osteoporosis outcomes: The
GENOMOS study. PLoS Med. 3:e902006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Steer CD, Emmett PM, Lewis SJ, Smith GD
and Tobias JH: Methylenetetrahydrofolate reductase (MTHFR) C677T
polymorphism is associated with spinal BMD in 9-year-old children.
J Bone Miner Res. 24:117–124. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Styrkarsdottir U, Halldorsson BV,
Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T,
Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, et al:
Multiple genetic loci for bone mineral density and fractures. N
Engl J Med. 358:2355–2365. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abrahamsen B, Jørgensen HL, Nielsen TL,
Andersen M, Haug E, Schwarz P, Hagen C and Brixen K: MTHFR
c.677C>T polymorphism as an independent predictor of peak bone
mass in Danish men-results from the odense androgen study. Bone.
38:215–219. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maloney KW, Shuster JJ, Murphy S, Pullen J
and Camitta BA: Long-term results of treatment studies for
childhood acute lymphoblastic leukemia: Pediatric oncology group
studies from 1986–1994. Leukemia. 14:2276–2285. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Riehm H, Reiter A, Schrappe M, Berthold F,
Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B and Henze G:
The in vivo response on corticosteroid therapy as an additional
prognostic factor in childhood acute lymphoblastic leukemia
(therapy study ALL-BFM 83). Klin Padiatr. 199:151–160. 1987.(In
German). View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reiter A, Schrappe M, Ludwig WD, Hiddemann
W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W and
Niethammer D: Chemotherapy in 998 unselected childhood acute
lymphoblastic leukemia patients. Results and conclusions of the
multicenter trial ALL-BFM 86. Blood. 84:3122–3133. 1994.PubMed/NCBI
|
|
23
|
Schrappe M, Reiter A, Ludwig WD, Harbott
J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl
F, et al: Improved outcome in childhood acute lymphoblastic
leukemia despite reduced use of anthracyclines and cranial
radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss
ALL-BFM study group. Blood. 95:3310–3322. 2000.PubMed/NCBI
|
|
24
|
Möricke A, Reiter A, Zimmermann M, Gadner
H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R,
et al: Risk-adjusted therapy of acute lymphoblastic leukemia can
decrease treatment burden and improve survival: Treatment results
of 2169 unselected pediatric and adolescent patients enrolled in
the trial ALL-BFM 95. Blood. 111:4477–4489. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fronkova E, Mejstrikova E, Avigad S, Chik
KW, Castillo L, Manor S, Reznickova L, Valova T, Zdrahalova K,
Hrusak O, et al: Minimal residual disease (MRD) analysis in the
non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Is it
possible to avoid MRD testing? Leukemia. 22:989–997. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
National Cancer Institute Common toxicity
criteria manual. version 2.0. Available on-line at. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcmanual_v4_10-4-99.pdfAccessed.
August 03–2014
|
|
27
|
Ogino S and Wilson RB: Genotype and
haplotype distributions of MTHFR677C>T and 1298A>C single
nucleotide polymorphisms: A meta-analysis. J Hum Genet. 48:1–7.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aricò M, Boccalatte MF, Silvestri D,
Barisone E, Messina C, Chiesa R, Santoro N, Tamaro P, Lippi A,
Gallisai D, et al: Osteonecrosis: An emerging complication of
intensive chemotherapy for childhood acute lymphoblastic leukemia.
Haematologica. 88:747–753. 2003.PubMed/NCBI
|
|
29
|
Burger B, Beier R, Zimmermann M, Beck JD,
Reiter A and Schrappe M: Osteonecrosis: A treatment related
toxicity in childhood acute lymphoblastic leukemia
(ALL)-experiences from trial ALL-BFM 95. Pediatr Blood Cancer.
44:220–225. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Davies JH, Evans BA, Jenney ME and Gregory
JW: In vitro effects of combination chemotherapy on osteoblasts:
Implications for osteopenia in childhood malignancy. Bone.
31:319–326. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karas-Kuzelicki N and Mlinaric-Rascan I:
Individualization of thiopurine therapy: Thiopurine
S-methyltransferase and beyond. Pharmacogenomics. 10:1309–1322.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maltzman JS and Koretzky GA: Azathioprine:
Old drug, new actions. J Clin Invest. 111:1122–1124. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hernigou P, Beaujean F and Lambotte JC:
Decrease in the mesenchymal stem-cell pool in the proximal femur in
corticosteroid-induced osteonecrosis. J Bone Joint Surg Br.
81:349–355. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yin L, Li YB and Wang YS:
Dexamethasone-induced adipogenesis in primary marrow stromal cell
cultures: Mechanism of steroid-induced osteonecrosis. Chin Med J
(Engl). 119:581–588. 2006.PubMed/NCBI
|
|
35
|
Muller I, Vaegler M, Holzwarth C,
Tzaribatchev N, Pfister SM, Schütt B, Reize P, Greil J,
Handgretinger R and Rudert M: Secretion of angiogenic proteins by
human multipotent mesenchymal stromal cells and their clinical
potential in the treatment of avascular osteonecrosis. Leukemia.
22:2054–2061. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vaes BL, Lute C, van der Woning SP, Piek
E, Vermeer J, Blom HJ, Mathers JC, Müller M, de Groot LC and
Steegenga WT: Inhibition of methylation decreases osteoblast
differentiation via a non-DNA-dependent methylation mechanism.
Bone. 46:514–523. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nakamura T, Imai Y, Matsumoto T, Sato S,
Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, et
al: Estrogen prevents bone loss via estrogen receptor alpha and
induction of Fas ligand in osteoclasts. Cell. 130:811–823. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ioannidis JP, Stavrou I, Trikalinos TA,
Zois C, Brandi ML, Gennari L, Albagha O, Ralston SH and Tsatsoulis
A: ER-alpha Genetics Meta-Analysis: Association of polymorphisms of
the estrogen receptor alpha gene with bone mineral density and
fracture risk in women: A meta-analysis. J Bone Miner Res.
17:2048–2060. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Boot AM, van der Sluis IM, de Muinck
Keizer-Schrama SM, van Meurs JB, Krenning EP, Pols HA and
Uitterlinden AG: Estrogen receptor alpha gene polymorphisms and
bone mineral density in healthy children and young adults. Calcif
Tissue Int. 74:495–500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Maruyama H, Toji H, Harrington CR, Sasaki
K, Izumi Y, Ohnuma T, Arai H, Yasuda M, Tanaka C, Emson PC, et al:
Lack of an association of estrogen receptor alpha gene
polymorphisms and transcriptional activity with Alzheimer disease.
Arch Neurol. 57:236–240. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Riggs BL: The mechanisms of estrogen
regulation of bone resorption. J Clin Invest. 106:1203–1204. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
te Winkel ML, van Beek RD, de Muinck
Keizer-Schrama SM, Uitterlinden AG, Hop WC, Pieters R and van den
Heuvel-Eibrink MM: Pharmacogenetic risk factors for altered bone
mineral density and body composition in pediatric acute
lymphoblastic leukemia. Haematologica. 95:752–759. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Raisz LG: Pathogenesis of osteoporosis:
Concepts, conflicts, and prospects. J Clin Invest. 115:3318–3325.
2005. View Article : Google Scholar : PubMed/NCBI
|
